OPHIDIAN PHARMACEUTICALS INC
10-Q, EX-27, 2000-08-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: OPHIDIAN PHARMACEUTICALS INC, 10-Q, 2000-08-14
Next: RADISYS CORP, 10-Q, 2000-08-14



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>                     <C>
<PERIOD-TYPE>                   9-MOS                   9-MOS
<FISCAL-YEAR-END>                          SEP-30-1999             SEP-30-1998
<PERIOD-END>                               JUN-30-2000             JUN-30-1999
<CASH>                                         990,179               4,849,773
<SECURITIES>                                         0                       0
<RECEIVABLES>                                    5,666                   5,112
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                               998,473               4,942,629
<PP&E>                                       5,370,290               1,907,313
<DEPRECIATION>                               1,115,929                 783,639
<TOTAL-ASSETS>                               6,788,817               7,954,660
<CURRENT-LIABILITIES>                          506,832                 381,033
<BONDS>                                              0                       0
                                0                       0
                                          0                       0
<COMMON>                                         2,895                  23,058
<OTHER-SE>                                   4,291,112               7,208,818
<TOTAL-LIABILITY-AND-EQUITY>                 6,788,817               7,954,660
<SALES>                                              0                       0
<TOTAL-REVENUES>                             1,314,224                  15,365
<CGS>                                                0                       0
<TOTAL-COSTS>                                3,310,702               4,017,329
<OTHER-EXPENSES>                                     0                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                            (89,951)               (193,069)
<INCOME-PRETAX>                            (1,906,527)             (3,808,895)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                                  0                       0
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                               (1,906,527)             (3,808,895)
<EPS-BASIC>                                     (1.65)                  (0.41)
<EPS-DILUTED>                                   (1.65)                  (0.41)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission